Organoidsciences Ltd. (476040.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩5,850 (+0.00%) as of
Key statistics
- Market cap
- 38.53B
- Dividend yield
- 0.00%
- 52-week range
- 5,780.00 – 48,500.00
- Revenue (TTM)
- 2.29B
- Profit margin
- 0.00%
- Volume
- 16.09k
About Organoidsciences Ltd.
Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seongnam-si, South Korea
- Employees
- 99
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.